Recent Price Movement and Market Context
On 25 Nov 2025, Sandu Pharmaceuticals touched an intraday low of Rs.37.21, representing a 5.05% decline during the trading session. This price marks the lowest level the stock has traded at in the past year, underscoring a period of sustained pressure. Over the last three trading days, the stock has recorded a cumulative return of -11.13%, indicating a consistent downward trajectory.
The stock's performance today underperformed its sector peers by 3.81%, while broader market indices showed mixed signals. The Sensex opened 108.22 points higher but later retreated by 421.92 points, closing at 84,587.01, down 0.37%. Despite the Sensex trading near its 52-week high of 85,801.70 and maintaining bullish moving averages, Sandu Pharmaceuticals has not mirrored this positive momentum.
Sandu Pharmaceuticals is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning highlights the stock's weak short- to long-term price trends relative to market benchmarks.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Performance Over the Past Year
Sandu Pharmaceuticals has recorded a one-year return of -35.47%, contrasting with the Sensex's positive return of 5.59% over the same period. This underperformance extends beyond the last year, as the stock has consistently lagged behind the BSE500 benchmark in each of the previous three annual periods.
The stock's 52-week high was Rs.62.80, indicating a substantial decline of approximately 40.7% from that peak to the current 52-week low. This wide price range reflects significant volatility and investor caution surrounding the company.
Financial Metrics and Valuation
Examining Sandu Pharmaceuticals' financial fundamentals reveals several factors contributing to its current market position. The company’s average Return on Equity (ROE) over the long term stands at 3.73%, which is modest relative to industry standards. Net sales have grown at an annual rate of 4.69% over the past five years, while operating profit has shown a growth rate of 17.92% during the same period.
Despite these growth figures, the company’s ability to service its debt appears constrained, with an average EBIT to interest coverage ratio of 1.92. This ratio suggests limited buffer to cover interest expenses from operating earnings, which may weigh on investor sentiment.
In the most recent quarter ending March 2025, net sales were reported at Rs.14.07 crores, marking the lowest quarterly sales figure in recent periods. This flat sales performance may have contributed to the subdued market response.
Valuation Considerations
Sandu Pharmaceuticals is trading at a Price to Book Value ratio of 0.9, indicating that the stock is valued below its book value. This valuation level may be considered attractive relative to peers, reflecting market caution but also potential value recognition.
Over the past year, while the stock price has declined by 35.47%, the company’s profits have risen by 10.9%. The Price/Earnings to Growth (PEG) ratio stands at 2.3, suggesting that earnings growth is not fully reflected in the current share price.
Shareholding Pattern and Sector Position
The majority of Sandu Pharmaceuticals’ shares are held by non-institutional investors, which may influence trading dynamics and liquidity. The company operates within the Pharmaceuticals & Biotechnology sector, which has seen mixed performance amid broader market trends.
Holding Sandu Pharmaceuticals from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Challenges
Sandu Pharmaceuticals’ recent price decline to Rs.37.21 reflects a combination of factors including subdued sales growth, limited debt servicing capacity, and persistent underperformance relative to market benchmarks. The stock’s position below all major moving averages further emphasises the current bearish trend.
While the broader market, represented by the Sensex, maintains a near-record high and positive technical indicators, Sandu Pharmaceuticals has not participated in this upward momentum. The Pharmaceuticals & Biotechnology sector itself has experienced mixed results, with small-cap stocks leading gains but Sandu Pharmaceuticals lagging behind.
Investors and market participants will likely continue to monitor the company’s financial results and sector developments closely as the stock remains at its lowest level in a year.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
